Elsevier Launches The Hive for 2017 to Showcase Pharma and Biotech Startup Innovation
Elsevier, the information analytics company specializing in science and health, has announced that applications and nominations for The Hive, its innovation hub for biotech and pharmaceutical startups, are now open. This year, at least eight leading-edge startups working on innovative goals will be chosen to become part of The Hive, with an unlimited number of places for exceptional candidates. The Hive’s startups will receive complimentary access to Elsevier’s suite of digital solutions for 18 months – helping them rapidly advance their critical research, and improve productivity. The Hive, first launched in 2016, highlights the superior levels of innovation in the startup biotech and pharma sector; as well as demonstrating to larger companies, and other areas of the research community, how R&D challenges can be overcome.
“We created The Hive in 2016 to highlight the trend in the industry that has seen biotech and pharma start-ups become centers of cutting-edge science. This trend is continuing in 2017 – many of the most promising drug candidates and discoveries in R&D pipelines originate from these early stage companies,” commented Tamas Szarvas, CMO, Corporate R&D, Elsevier’s R&D Solutions. “In 2017, The Hive will continue to highlight the fresh, innovative and agile world of R&D that is taking place within startups, and we look forward to welcoming a new group of participants. Additionally, we know that the industry is always looking to learn from these innovation powerhouses, and The Hive offers a far-reaching platform for sharing success stories.”
Elsevier’s R&D Solutions are utilized every day across the life science industry to enable research and accelerate confident decision making in drug discovery and development. The industry faces significant challenges; from overcoming antibiotic resistance in the absence of new drugs, to reducing the chance of unanticipated adverse events, to being able to deliver on the promise of precision medicine. For the industry to make meaningful impact, access to the latest insights from data, powerful analytics, and technologies to help R&D professionals, is essential. For the startups that will be joining The Hive, Elsevier’s R&D Solutions will help them achieve faster scientific breakthroughs, giving them the potential to change the industry’s landscape and improve the lives of patients.
“Being part of The Hive has given exposure to our company and the team’s work. It has also allowed hands-on training for programs that will help us make better-informed decisions on lead compound selections, and increase our productivity by reducing our efforts spent on finding everything that is relevant and trustworthy for our research,” commented Claudia A. McDonald Bøen, Ph.D., CEO of 2016 participant in The Hive, Arctic Pharma AS. “Elsevier’s solutions contain extensive and detailed information on chemical compounds/structures, visualization of disease mechanisms, metabolomics data, and predictions on drug-drug interactions – all of which are important to further develop our cancer therapies.”
"A significant challenge for any company developing a broadly applicable platform technology is to quickly gather, assess, and act upon information across the many different disease and technical areas associated with drug candidate development. Areas of research cover the science and biology of course; as well as IP, clinical, and commercial considerations. But that’s what is great about being part of The Hive. Participation has provided us with an amazing array of resources with which to successfully meet this challenge," commented Tom Wickham, Vice President R&D at Rubius Therapeutics, participant in The Hive 2016.
The top candidates for The Hive 2017 are pre-revenue pharmaceutical and biotech startups, and other small companies, that are actively involved in the advancement of early stage research; with a minimum of ten scientists on staff. Enrollment for The Hive is open now and candidate companies may apply or can be nominated. Candidates will complete a questionnaire about their research, funding and goals for the next 18 months; followed by Elsevier’s Solution Finder to assess which solutions will be most beneficial. Prior to final selection, designated candidates will then be invited to undertake a phone interview.
To apply to join The Hive, please visit: https://www.elsevier.com/rd-solutions/pharma-and-life-sciences-solutions/thehive/join.
This article has been republished from materials provided by Elsevier. Note: material may have been edited for length and content. For further information, please contact the cited source.
Targeted Drug Could be Used to Treat Advanced Cancers Located Anywhere in the BodyNews
A new targeted drug could be used to treat a small number of advanced cancers no matter where they grow in the body.READ MORE
Human Malaria Parasites Grown for the First Time in Dormant FormNews
One of the biggest obstacles to eradicating malaria is a dormant form of the parasite which is resistant to most antimalarial drugs and can reawaken years later, causing disease relapse. Researchers have shown they can grow the dormant parasite in engineered human liver tissue for several weeks, allowing them to closely study how the parasite becomes dormant, what vulnerabilities it may have, and how it springs back to life.READ MORE